Greenleaf Trust Raises Holdings in Illumina, Inc. (NASDAQ:ILMN)

Greenleaf Trust lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 7.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,659 shares of the life sciences company’s stock after buying an additional 341 shares during the quarter. Greenleaf Trust’s holdings in Illumina were worth $608,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ILMN. UMB Bank n.a. boosted its position in shares of Illumina by 7.0% during the 2nd quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock worth $140,000 after purchasing an additional 88 shares in the last quarter. Texas Permanent School Fund Corp grew its position in Illumina by 0.3% during the first quarter. Texas Permanent School Fund Corp now owns 32,818 shares of the life sciences company’s stock worth $4,507,000 after buying an additional 114 shares during the period. Institute for Wealth Management LLC. increased its holdings in Illumina by 4.6% in the second quarter. Institute for Wealth Management LLC. now owns 2,728 shares of the life sciences company’s stock valued at $285,000 after buying an additional 119 shares in the last quarter. Massmutual Trust Co. FSB ADV increased its holdings in Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after buying an additional 168 shares in the last quarter. Finally, Empirical Finance LLC lifted its position in shares of Illumina by 3.6% during the 1st quarter. Empirical Finance LLC now owns 5,602 shares of the life sciences company’s stock valued at $769,000 after acquiring an additional 193 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several research analyst reports. Leerink Partners raised their price objective on Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Daiwa America raised Illumina to a “strong-buy” rating in a research note on Friday, August 16th. HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a research note on Thursday, October 17th. Hsbc Global Res upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $252.00 price target on shares of Illumina in a research report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $154.33.

Illumina Stock Up 0.4 %

Shares of ILMN opened at $141.95 on Friday. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $151.40. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.04. The stock’s fifty day simple moving average is $134.30 and its 200 day simple moving average is $121.64.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.24. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period last year, the business posted $0.32 EPS. The company’s quarterly revenue was down 5.4% compared to the same quarter last year. Equities research analysts expect that Illumina, Inc. will post 3.63 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.